Case Series
Eye (2007) 21, 824–825; doi:10.1038/sj.eye.6702352; published online 7 April 2006
Adalimumab for sight-threatening uveitis in Behçet's disease
B Mushtaq1, T Saeed1, R D Situnayake2 and P I Murray1
- 1Birmingham and Midland Eye Centre, Birmingham, UK
- 2City Hospital, Birmingham, UK
Correspondence: PI Murray, Academic Unit of Ophthalmology, Division of Immunity and Infection, University of Birmingham, Birmingham and Midland Eye Centre, Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, Birmingham B18 7QU, UK. Tel: +44 121 507 6851; Fax: +44 121 507 6853; E-mail: p.i.murray@bham.ac.uk
Received 28 November 2005; Accepted 3 March 2006; Published online 7 April 2006.
Abstract
Aims
To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy.
Methods
Case note review. Main outcome measure was recurrence of uveitis.
Results
All patients remained free of recurrence with stable visual acuities.
Conclusions
Adalimumab appears to maintain disease remission in Behçet's disease.
Keywords:
uveitis, Behçet's disease, therapy, adalimumab
